Serina Therapeutics, Inc., a privately-held, clinical-stage biotechnology company developing therapies for the treatment of Parkinson’s Disease and other neurological diseases, entered into a merger agreement with AgeX Therapeutics, Inc. Under terms of the agreement, Serina will merge with a wholly-owned subsidiary of AgeX in an all-stock transaction. The combined company will continue under the Serina Therapeutics name and will focus on advancing Serina’s pipeline of small molecule drug cand...